Open Access

Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes

Anze Smole

Anze Smole

Immunology and Cellular Immunotherapy (ICI) Group, Department of Genetic Toxicology and Cancer Biology, National Institute of BiologyLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Smole, Anze
  
Dec 13, 2022
Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes's Cover Image
About this article
Previous Article
Next Article
Cite
Download Cover
Article Category: review
Published Online: Dec 13, 2022
Page range: 409 - 419
Received: Oct 19, 2022
Accepted: Oct 27, 2022
DOI: https://doi.org/10.2478/raon-2022-0049
Keywords
© 2022 Anze Smole, published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.

Figure 1

The principle of adoptive cellular immunotherapy. CAR = chimeric antigen receptor; TCR = T-cell receptor
The principle of adoptive cellular immunotherapy. CAR = chimeric antigen receptor; TCR = T-cell receptor

Figure 2

Schematics of the basic CAR architecture. CAR = chimeric antigen receptor; scFv = single-chain variable fragment
Schematics of the basic CAR architecture. CAR = chimeric antigen receptor; scFv = single-chain variable fragment

Figure 3

Challenges of cellular immunotherapy with chimeric antigen receptor (CAR) T cells.
Challenges of cellular immunotherapy with chimeric antigen receptor (CAR) T cells.
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
Journal RSS Feed